<DOC>
	<DOCNO>NCT00138671</DOCNO>
	<brief_summary>A One Year Clinical Trial Assessing Usefulness Safety Inhaled Insulin Diabetics Chronic Obstructive Pulmonary Disease .</brief_summary>
	<brief_title>A One Year Clinical Trial Assessing Usefulness Safety Inhaled Insulin Diabetics With COPD</brief_title>
	<detailed_description>Pfizer announce October 2007 would stop marketing Exubera . At time recruitment study A2171030 place hold . Nektar , company Pfizer license Exubera , announce April 9 , 2008 stop search new marketing partner . Accordingly , commercial availability Exubera . As result , study A2171030 terminate June 17 , 2008 . Neither safety efficacy reason cause study termination .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Diabetes Mellitus ( Type 1 Type 2 ) currently control inject insulin Prior smoker fix airflow obstruction screening ( FEV1/FVC &lt; 70 % ) FEV1 &lt; 80 % predict and/or history chronic productive cough . Poorly control , unstable steroiddependent COPD , insulin pump therapy , active smoking</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>77 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>